DJIA51461.90 -631.21
S&P 5007551.81 -33.92
NASDAQ25978.42 -3.15
Russell 20002858.81 -11.48
German DAX25537.75 135.47
FTSE 10010688.47 30.34
CAC 408140.59 50.31
EuroStoxx 506271.95 33.85
Nikkei 22563923.00 438.90
Hang Seng24713.78 46.54
Shanghai Comp3891.60 27.32
KOSPI6717.97 90.71
Bloomberg Comm IDX141.42 -5.85
WTI Crude-fut100.65 -2.28
Brent Crude-fut100.89 3.57
Natural Gas3.02 0.08
Gasoline-fut3.23 -0.24
Gold-fut4301.20 -36.80
Silver-fut63.42 -0.87
Platinum-fut1759.10 -26.50
Palladium-fut1286.00 -30.00
Copper-fut6.44 -0.03
Aluminum-spot3195.00 0.00
Coffee-fut281.55 1.80
Soybeans-fut1325.25 3.75
Wheat-fut728.50 -4.00
Bitcoin76059.44 474.16
Ethereum USD2407.85 12.21
Litecoin51.17 -0.06
Dogecoin0.08 0.00
EUR/USD1.1527 -0.0016
USD/JPY155.17 -0.04
GBP/USD1.3450 -0.0038
USD/CHF0.8191 -0.0003
USD IDX100.31 0.69
US 10-Yr TR4.983 -0.021
GER 10-Yr TR3.513 0.002
UK 10-Yr TR5.3083 0.0057
JAP 10-Yr TR2.985 -0.011
Fed Funds3.75 0
SOFR3.64 0.02
High-rise commercial buildings

Sub Markets

Topics

Direct Investment  + CLOs  | 
Caris Life Sciences Hauls $400M in Senior Secured Debt Funding

Caris Life Sciences Hauls $400M in Senior Secured Debt Funding

Caris Life Sciences, a molecular and science technology company, closed a senior secured term loan of $400 million. Backing the loan are life sciences investment firms OrbiMed and Braidwell; the former led the financing and also participated in Caris’ last two fundraising rounds.

Along with paying off other outstanding debt, the Irving, TX-based company will use the funds to continue building out its precision medicine platform, which uses artificial intelligence to sift through an individual’s entire genome for signs of cancer and predict how they’ll respond to various treatments.

“We are making breakthroughs with artificial intelligence and machine learning that enhance and change our understanding of cancer as a disease. This additional capital will allow us to pursue that mission with even more intense focus as we invest in our technologies and product pipeline,” said David Halbert, Caris’ founder and CEO.

OrbiMed participated in Caris’ $830 million equity financing round in 2021 and $310 million growth capital financing round in 2020, which had given the company a nearly $8bn valuation. Braidwell is a new investor in the company.

With the latest injection of funds, Caris’ total capital raised since 2018 is approximately $1.7 billion.

Connect

Inside The Story

Caris Life Sciences

About Joe Palmisano

Joe Palmisano is editorial director of Connect Money, where he oversees daily coverage of alternative assets, direct investments, financial advisory and the economy. He brings three decades of experience as a financial journalist, analyst and portfolio manager. Before joining Connect Money, Palmisano wrote for The Wall Street Journal, covering foreign exchange, global fixed-income and equity markets. He later served as a senior research analyst and portfolio manager, producing market analysis and managing foreign exchange and U.S. equity portfolios for FX Concepts. His work has also appeared in SFO Magazine and CMT Association publications. Palmisano earned a bachelor’s degree in finance from The American University and holds the Chartered Market Technician (CMT) designation and is a member of the CFA Institute.